News
Drug and biotech news
Last checked: Nov 19, 2026Source: BioPharma Dive, STAT (pharma), FDA press releases, FDA MedWatch, Drugs@FDA (new approvals), openFDA (Class I recalls)
Today's digest
The week's most consequential drug and biotech stories, picked and summarized by Claude (Anthropic's AI) from the headlines below. It can make mistakes; read the linked story.
80 stories
- FDAFDA MedWatchNov 19, 2026Early Alert: Outset Medical Updates Use Instructions for the Tablo Console and the TabloCart with Prefiltration Drawer
Outset Medical Tablo Console and TabloCart with Prefiltration Drawer power cord connections may overheat, posing fire, burn, and treatment interruption risks.
- Trade pressSTAT (pharma)Nov 18, 2026STAT+: NIH to move last group of its research chimps to a sanctuary
The last chimpanzees owned by the U.S. government and still living in a laboratory will be moved to a sanctuary next year.
- Trade pressSTAT (pharma)Nov 18, 2026STAT+: 7 burning questions about the FDA’s post-Overton future
STAT tackles the most important questions about the FDA's uncertain future.
- FDAFDA press releasesNov 18, 2026FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease
FDA today approved Infilbray (venglustat) tablets, the first treatment for the neurological symptoms of Type 3 Gaucher disease (GD3) in adults and pediatric patients weighing at least 15 kg (approximately 33 pounds).
- Trade pressBioPharma DiveNov 18, 2026‘Selling and marketing snake oil’: The debate over compounded GLP-1s
Proponents of compounding argue it increases access, lowers prices and helps patients who may need individualized versions of a drug. But there are serious concerns, experts said at the HLTH conference.
- Trade pressBioPharma DiveNov 18, 2026White House pulls nomination for FDA nominee Overton
The sudden end of Heidi Overton's candidacy likely ensures a Democrat-controlled Congress will choose the FDA's next leader - but shouldn't disrupt the agency, analysts say.
- Trade pressBioPharma DiveNov 18, 2026Pfizer leaps into ‘in vivo’ CAR-T with latest China deal
The potentially $2.6 billion collaboration puts Pfizer into a competitive race to treat autoimmune conditions by reprogramming cells inside the body.
- Trade pressSTAT (pharma)Nov 18, 2026STAT+: FDA discloses reasons for rejecting Summit drug
The FDA published its complete response letter to Summit Therapeutics explaining why it rejected the biotech's closely watched lung cancer drug:
- Trade pressSTAT (pharma)Nov 18, 2026STAT+: Pharmalittle: We're reading about Overton FDA nomination being yanked, a Merck setback, and more
The Trump administration is pulling the nomination of Heidi Overton to lead the FDA over concerns she lacked support to get confirmed by the Senate
- Trade pressBioPharma DiveNov 18, 2026FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK
The FDA had several issues with ivonescimab, according to the letter. Elsewhere, Sellas shares rocketed on results for a leukemia vaccine and Biogen and Lilly struck up new R&D pacts.
- FDAFDA press releasesNov 17, 2026FDA Launches the Global Reliance Disclosure Program to Expand Patient Access to Medicines Worldwide
FDA today announced the Global Reliance Disclosure Program (GRDP), a landmark initiative that will fundamentally transform how the FDA's regulatory drug and biologic approval decisions are leveraged by health...
- FDAFDA press releasesNov 17, 2026FDA Approves First Drug Shown to Help Patients with Infantile-Onset Niemann-Pick Disease Type C Live Longer
FDA approved Lembaz (adrabetadex) injection, the first treatment shown to help people with a severe form of Niemann-Pick disease type C (NPC) live longer.
- Trade pressBioPharma DiveNov 17, 2026Roche breast cancer pill cleared by FDA
Wilserdly's U.S. approval is seen by analysts as a "key first step" in an important launch for Roche, which has claimed the drug could become its top-selling product.
- Trade pressSTAT (pharma)Nov 17, 2026STAT+: Flagship opens biotech-creation outpost in the U.K.
Flagship is putting up 100 million pounds to start “AI-native platform companies" focused on human and planetary health in the U.K.:
- Trade pressBioPharma DiveNov 17, 2026AI drugmaker Isomorphic restocks with $5B fundraise
Even as the larger AI industry faces turmoil, investors have given Isomorphic the two largest cash infusions in the biotech sector this year.
- Trade pressSTAT (pharma)Nov 17, 2026STAT+: 'Medicare for More' gains traction
Democrats coalesce around a new health care policy, and Trump's new chief of staff embraces MAHA.
- Trade pressSTAT (pharma)Nov 17, 2026STAT+: Pharmalittle: We're reading about a Roche breast cancer pill, obesity drugs in children, and more
The FDA approved a breast cancer drug from Roche, teeing up the launch of what the company has said could become its top-selling product
- Trade pressBioPharma DiveNov 17, 2026Marrow sets out to challenge genetic medicines for severe blood diseases
Armed with $173 million in venture funding, the startup is developing what it's positioning as a more accessible alternative to gene therapy and gene editing treatments for sickle cell and beta thalassemia.
- Trade pressSTAT (pharma)Nov 16, 2026STAT+: FDA approves new breast cancer drug, providing new option for some patients, boost for Roche
The FDA approved a new breast cancer drug from Roche, teeing up the launch of a medicine the company has said could become its top-selling product ever.
- Trade pressSTAT (pharma)Nov 16, 2026STAT+: In a win for MAHA, FDA creates new regulatory category for the supplement NAC
The supplement NAC has been widely available for years, but exists in a legal gray area.
- Trade pressSTAT (pharma)Nov 16, 2026STAT+: Newer GLP-1 drugs to combat obesity may be the next global battleground over access to medicines, expert warns
How obesity medications may become the next big battleground over access to medicines in lower-income countries.
- Trade pressBioPharma DiveNov 16, 2026Summit shares fall as FDA rejects closely watched PD-1/VEGF drug
The FDA refused to overlook ivonescimab's failure to initially extend survival in a form of lung cancer, setting back Summit's first chance to win a U.S. approval.
- Trade pressBioPharma DiveNov 16, 2026CG Oncology drug delivers ‘exceptional’ results in key bladder cancer trial
CG's therapy cretostimogene cut the risk of recurrence by 68% when administered after surgery, far surpassing Wall Street's expectations and lifting company shares.
- Trade pressBioPharma DiveNov 16, 2026J&J bets $2.2B on Ollin’s vision loss drug
The deal hands J&J a treatment that could complement its existing eye care franchise, but would vie for share of a crowded and competitive market.
- Trade pressSTAT (pharma)Nov 16, 2026STAT+: Biotech's rebound isn't lifting all boats equally
Biotech is having a good year, though you wouldn't necessarily know it from how investors are treating positive clinical data.
- Trade pressSTAT (pharma)Nov 16, 2026STAT+: Pharmalittle: We're reading about GLP-1 use, Covid-19 vaccine investment returns, and more
During July and August 2025, approximately 1 in 10 U.S. adults reported taking a GLP-1 medication during the previous year
- Trade pressSTAT (pharma)Nov 13, 2026STAT+: Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
- Trade pressSTAT (pharma)Nov 13, 2026STAT+: HHS plans funding for research into ibogaine for PTSD
The Trump administration will funnel up to $4.9 million into supporting research into ibogaine, a psychedelic that’s drawn interest as a potential treatment for PTSD and addiction.
- Trade pressSTAT (pharma)Nov 13, 2026STAT+: Pharmalittle: We're reading about Lilly conflict questions, a DEA OK for a narcolepsy pill, and more
A deal for smart-ring maker Oura to acquire a telehealth company is raising conflict-of-interest questions for Eli Lilly
- FDA approvalDrugs@FDANov 13, 2026FDA new use approved: Gazyva (Obinutuzumab), Genentech
Efficacy supplement 44. Priority review.
- FDA approvalDrugs@FDANov 13, 2026FDA novel drug approval: Klygefa (Gefurulimab), Alexion Pharm
To treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis Orphan.
- FDA approvalDrugs@FDANov 13, 2026FDA new use approved: Imfinzi (Durvalumab), Astrazeneca Uk LTD
Efficacy supplement 59. Priority review.
- FDA approvalDrugs@FDANov 13, 2026FDA new use approved: Zurzuvae (Zuranolone), Biogen
Efficacy supplement 4. Priority review.
- FDA approvalDrugs@FDANov 13, 2026FDA new use approved: Myqorzo (Aficamten), Cytokinetics
Efficacy supplement 2. Orphan.
- Trade pressSTAT (pharma)Nov 13, 2026STAT+: Oura’s acquisition of health tech startup raises conflict-of-interest questions for Eli Lilly, experts say
With a new deal announced this week, the relationship between Eli Lilly and a telehealth company that markets GLP-1s is expected to grow more complicated.
- Trade pressSTAT (pharma)Nov 12, 2026STAT+: Blackstone backs Pfizer's bet on monthly obesity treatment
Pfizer spent up to $10 billion to buy Metsera last year. Now, it’s bringing in private equity behemoth Blackstone to help pay for the deal.
- Trade pressSTAT (pharma)Nov 12, 2026STAT+: Will Heidi Overton get to run the FDA?
Does Heidi Overton have the votes ? And how will Dems take on RFK Jr.?
- Trade pressSTAT (pharma)Nov 12, 2026STAT+: Pharmalittle: We're reading about FDA shelving fast-track review, a Canadian importer arrested, and more
The FDA has shelved the fast-track drug review initiative launched in June 2025 by former Commissioner Marty Makary
- FDA approvalDrugs@FDANov 12, 2026FDA new approval: Pebrilzo (Pertuzumab), Biocon Biologics INC
- FDAFDA MedWatchNov 12, 2026Game Changer Products LLC Issues Voluntary Nationwide Recall of 10 Day Forecast Capsules Due to the Presence of Undeclared Sildenafil and Acetaminophen
FOR IMMEDIATE RELEASE – November 12, 2026 - Tampa, Florida. Game Changer Products LLC is voluntarily recalling all lots of 10 Day Forecast capsules to the consumer level. FDA analysis has found the product to be tainted...
- Trade pressSTAT (pharma)Nov 11, 2026STAT+: Most-favored nations policy makes drugmakers rethink launches abroad
Drug companies seem to be looking for workarounds to protect their U.S. sales against Trump's "most-favored nations" policy:
- FDA approvalDrugs@FDANov 10, 2026FDA novel drug approval: Pimjetmi (Pimicotinib), Emd Serono
To treat adults with symptomatic tenosynovial giant cell tumors in whom surgical resection may cause worsening functional limitation or severe morbidity
- FDAFDA press releasesNov 9, 2026FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High Risk
FDA today approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate...
- FDA approvalDrugs@FDANov 9, 2026FDA new approval: Oxderys (Doxorubicin Hydrochloride), Avyxa Holdings
- FDA approvalDrugs@FDANov 9, 2026FDA new approval: Multibic (Multibic), Fresenius Medical Care Renal Therapies Group LLC
- FDA approvalDrugs@FDANov 9, 2026FDA novel drug approval: Sunharbo (Asundexian), Bayer Healthcare
To reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack Priority review.
- FDAFDA MedWatchNov 9, 2026Eugia US LLC (f/k/a Auro Medics Pharma LLC) Issues Voluntary Nationwide Recall of Vancomycin Hydrochloride for Injection USP 1.25g/Vial-30mL (Single Dose Vial) Due to Presence of Particulate Matter
FOR IMMEDIATE RELEASE –November 06,2026 – East Windsor, New Jersey, Eugia US LLC (f/k/a Auro Medics Pharma LLC) is voluntarily recalling lot number 3VM26026A of Vancomycin Hydrochloride for Injection USP 1.25g/Vial-30mL...
- FDAFDA MedWatchNov 6, 2026MedWatch Alert: FDA Investigating Serious Risk of Malignancy Linked to Zolgensma Gene Therapy
FDA Investigating Serious Risk of Malignancy Linked to Zolgensma Gene Therapy: FDA Safety Communication
- FDAFDA press releasesNov 5, 2026FDA Grants Accelerated Approval to a New Treatment for Head and Neck Squamous Cell Carcinoma
The U.S. Food and Drug Administration today granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and neck squamous cell...
- FDA approvalDrugs@FDANov 5, 2026FDA new use approved: Rybrevant Faspro (Amivantamab and Hyaluronidase-Lpuj), Janssen Biotech
Efficacy supplement 2. Priority review.
- FDAFDA press releasesNov 2, 2026FDA Provides Clarity to Support Cell and Gene Therapy Development and Quality
The U.S. Food and Drug Administration today issued final guidance for manufacturers of cellular and gene therapy (CGT) products to implement a comprehensive, science- and risk-based plan for making sure their products...
- FDAFDA press releasesOct 30, 2026FDA Approves First Plasmid DNA-based Immunotherapy for Adults with Recurrent Respiratory Papillomatosis
The U.S. Food and Drug Administration today granted accelerated approval for Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for treatment of adults with recurrent respiratory papillomatosis (RRP).
- FDA approvalDrugs@FDAOct 29, 2026FDA new approval: Axycis (Cisplatin), Avyxa Holdings
- FDA approvalDrugs@FDAOct 27, 2026FDA new approval: Lucamzi (Ranibizumab-Blrz), Xbrane Biopharma Ab
- FDA approvalDrugs@FDAOct 26, 2026FDA new use approved: Talzenna (Talazoparib Tosylate), Pfizer
Efficacy supplement 14. Priority review.
- FDA approvalDrugs@FDAOct 26, 2026FDA new use approved: Talzenna (Talazoparib Tosylate), Pfizer
Efficacy supplement 4. Priority review.
- FDA approvalDrugs@FDAOct 23, 2026FDA new use approved: Skyrizi (Risankizumab-Rzaa), Abbvie INC
Efficacy supplement 53. Orphan, Priority review.
- FDA approvalDrugs@FDAOct 23, 2026FDA new use approved: Awiqli Flextouch (Insulin Icodec), Novo Nordisk INC
Efficacy supplement 1. Priority review.
- FDA approvalDrugs@FDAOct 22, 2026FDA new approval: Enzeevu (Aflibercept-Abzv), Sandoz INC
- FDA approvalDrugs@FDAOct 22, 2026FDA new approval: Ahzantive (Aflibercept-Mrbb), Formycon AG
- FDA approvalDrugs@FDAOct 22, 2026FDA new approval: Pavblu (Aflibercept-Ayyh), Amgen INC
- FDA approvalDrugs@FDAOct 21, 2026FDA new use approved: Ultomiris (Ravulizumab-Cwvz), Alexion Pharm
Efficacy supplement 46. Orphan, Priority review.
- FDAFDA MedWatchOct 21, 2026Wedgewood Pharmacy Issues Recall of Certain Compounded Veterinary Medications Within Expiry Due to Potential Potency Issues
SWEDESBORO, N.J., (October 21, 2026) - Wedgewood Pharmacy LLC ("Wedgewood") is recalling certain compounded veterinary medications within expiry at the provider/customer level due to inconsistencies in the reliability...
- FDAFDA press releasesOct 20, 2026FDA Approves First-of-Its-Kind Chronic Hepatitis B Treatment
FDA today approved Hibsago (bepirovirsen) injection, in combination with existing antiviral therapy, to treat chronic hepatitis B virus (HBV) infection in certain adults without cirrhosis.
- FDAFDA press releasesOct 20, 2026FDA Approves Once-Weekly Generic Hormone Therapy Patch for Women
Today, the U.S. Food and Drug Administration approved the first generic of Climara Pro (estradiol and levonorgestrel transdermal system, 0.045 mg per day/0.015 mg), a transdermal hormone therapy patch for women with an...
- FDAFDA press releasesOct 20, 2026FDA Issues Final Guidance on Prescription Drug Apps and Software
The U.S. Food and Drug Administration today released final guidance establishing a clear framework for how drug companies can develop, distribute, and label apps used alongside their prescription medicines.
- FDA approvalDrugs@FDAOct 20, 2026FDA novel drug approval: Hibsago (Bepirovirsen Sodium), Glaxosmithkline
To treat chronic hepatitis B virus infection in certain adults without cirrhosis, in combination with existing antiviral therapy Priority review.
- FDAFDA press releasesOct 19, 2026FDA Approves Immunotherapy That May Allow Certain Patients with Rectal Cancer to Avoid Chemotherapy, Radiation and Surgery
The U.S. Food and Drug Administration today granted accelerated approval for a new use of the immunotherapy Jemperli (dostarlimab-gxly) that may allow some patients with locally advanced rectal cancer to avoid common...
- FDA approvalDrugs@FDAOct 19, 2026FDA new approval: Calrezdy (Calcium Chloride), Fresenius Medcl Care
- FDA approvalDrugs@FDAOct 19, 2026FDA new use approved: Jemperli (Dostarlimab-Gxly), Glaxosmithkline
Efficacy supplement 15. Priority review.
- FDA approvalDrugs@FDAOct 19, 2026FDA new approval: Cienby (Trisodium Citrate), Fresenius Medcl Care
- FDA approvalDrugs@FDAOct 16, 2026FDA new use approved: Ayvakit (Avapritinib), Blueprint Medicines
Efficacy supplement 21. Orphan.
- FDA approvalDrugs@FDAOct 16, 2026FDA new approval: Brytly (Apraclonidine Hydrochloride), Alcon Labs INC
- FDA approvalDrugs@FDAOct 16, 2026FDA new approval: Yulzety (Rivaroxaban), Rosemont Pharms
- FDA approvalDrugs@FDAOct 16, 2026FDA new use approved: Keytruda (Pembrolizumab), Merck Sharp Dohme
Efficacy supplement 191. Orphan.
- FDA approvalDrugs@FDAOct 15, 2026FDA new approval: Evoxac (Cevimeline Hydrochloride), Cosette
- FDA approvalDrugs@FDAOct 15, 2026FDA new use approved: Enspryng (Satralizumab), Genentech
Efficacy supplement 8. Priority review.
- FDA approvalDrugs@FDAOct 15, 2026FDA new use approved: Zilbrysq (Zilucoplan Sodium), Ucb INC
Efficacy supplement 15. Orphan.
- FDAFDA press releasesOct 14, 2026FDA Launches the Rare Disease Framework Initiative to Develop a Holistic, Fit-For-Purpose Framework for Rare Disease Drug Development
The U.S. Food and Drug Administration, a division within the U.S. Department of Health and Human Services (HHS), today announced the Rare Disease Framework Initiative to reimagine the development of drugs and biologics...
- FDAFDA press releasesOct 14, 2026FDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder Cancer
FDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder Cancer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.